Compare Inovio Pharmaceuticals Inc (INO) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Financial Select Sector SPDR Fund — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Financial Select Sector SPDR Fund trades at $57.92. The key difference: Financial Select Sector SPDR Fund is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | XLF | |
|---|---|---|
Market Cap | $78.55M | — |
Sector | Health | — |
52-Week High | $2.87 | $58.01 |
52-Week Low | $0.66 | $47.80 |
Enterprise Value | $49.56M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
XLF, the Financial Select Sector SPDR ETF, trades at $57.73, down 0.14% on the day, with a bullish technical signal driven by moving averages. The ETF recently crossed above its 200-day moving average and hit a record high, supported by strong inflows into sector ETFs. A dividend of $0.19 is scheduled for June 2026.
Outlook remains positive given sector momentum and AI-driven opportunities, though overbought RSI levels and concentration risks warrant caution. Financials benefit from robust bank earnings and market broadening, but interest rate sensitivity and valuation pressures pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
